Zacks Research decreased their Q1 2025 EPS estimates for CRISPR Therapeutics in a report issued on Wednesday, February 5th. Zacks Research analyst R. Department now anticipates that the company will ...

Scientists in the polo-obsessed nation have produced world's first genetically edited horses, designed to outrun champion ...

Researchers developed an epigenetic editing approach to silence the PCSK9 gene, achieving long-term cholesterol reduction ...

New gene therapy modalities, such as CRISPR guide RNA (single guide ribonucleic acid [sgRNA]) and messenger RNA (mRNA), ...

A temporally resolved CRISPR-Cas9 screen reveals DAC-induced DNA damage drives trans-cell cycle cytotoxicity that depends on ...

Biohacking has moved from niche experiments to a global movement reshaping how we think about human potential. With ...

This study presents an optimized CRISPR-Cas12a system for large-scale genetic screening, revealing critical genes involved in lymphoma development and therapy.

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is a pioneer in gene-editing technology, using its patented gene sequencing platform to ...

Variant Bio recently announced a multimillion-dollar deal with a pharmaceutical company, and some of that money will go to ...